Naringin Inhibits Multiple Myeloma Cells Proliferation by Altering Mitochondrial Function

Abstract

This study was conducted to evaluate the effect of Naringin (NAR) on multiple myeloma cells through assessment of cell proliferation and mitochondrial function. Methods: Human myeloma cell line (KMS-20) was subjected to normal (control) and treatment conditions. The viability, toxicity, cardiolipin content and mitochondrial membrane potential of KMS-20 cells in all groups were analyzed by using suitable kits. Results: The obtained data showed that NAR is toxic and inhibits the growth of KMS-20 cells. Similar to Doxorubicin (DOX)-treated cell group, the KMS-20 cell group supplemented with NAR had a sharp decrease in cardiolipin content compared to those in control group. The cardiolipin contents of KMS-20 cells in the DOX- and NAR-treated groups were 38.78±3.74 and 47.23±4.65 (% of control, p<0.05), respectively. In contrast to DOX, NAR strongly elevated the mitochondrial membrane potential of the KMS-20 cells. Conclusion: This study shows that NAR has the ability to inhibit the growth of KMS-20 multiple myeloma celline by altering their mitochondrial structure and function.